Decorin and biglycan retain LDL in disease-prone valvular and aortic subendothelial intimal matrix

Rajamannan, 2011, Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update, Circulation, 124, 1783, 10.1161/CIRCULATIONAHA.110.006767 Grande-Allen, 2007, Glycosaminoglycan synthesis and structure as targets for the prevention of calcific aortic valve disease, Cardiovasc Res, 76, 19, 10.1016/j.cardiores.2007.05.014 O'Brien, 2006, Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more), Arterioscler Thromb Vasc Biol, 26, 1721, 10.1161/01.ATV.0000227513.13697.ac Rajamannan, 2006, Calcific aortic stenosis: a disease ready for prime time, Circulation, 114, 2007, 10.1161/CIRCULATIONAHA.106.657759 Agmon, 2001, Aortic valve sclerosis and aortic atherosclerosis: different manifestations of the same disease? Insights from a population-based study, J Am Coll Cardiol, 38, 827, 10.1016/S0735-1097(01)01422-X Tabas, 2007, Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications, Circulation, 116, 1832, 10.1161/CIRCULATIONAHA.106.676890 Williams, 1995, The response-to-retention hypothesis of early atherogenesis, Arterioscler Thromb Vasc Biol, 15, 551, 10.1161/01.ATV.15.5.551 Nakashima, 2007, Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration, Arterioscler Thromb Vasc Biol, 27, 1159, 10.1161/ATVBAHA.106.134080 O'Brien, 1996, Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis, Arterioscler Thromb Vasc Biol, 16, 523, 10.1161/01.ATV.16.4.523 Stewart, 1997, Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study, J Am Coll Cardiol, 29, 630, 10.1016/S0735-1097(96)00563-3 Weiss, 2006, Calcific aortic valve stenosis in old hypercholesterolemic mice, Circulation, 114, 2065, 10.1161/CIRCULATIONAHA.106.634139 Miller, 2009, Lowering plasma cholesterol levels halts progression of aortic valve disease in mice, Circulation, 119, 2693, 10.1161/CIRCULATIONAHA.108.834614 Camejo, 1982, The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: its possible role in atherogenesis, Adv Lipid Res, 19, 1, 10.1016/B978-0-12-024919-0.50007-2 Jackson, 1991, Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes, Physiol Rev, 71, 481, 10.1152/physrev.1991.71.2.481 O'Brien, 1998, Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins, Circulation, 98, 519, 10.1161/01.CIR.98.6.519 Camejo, 1998, Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis, Atherosclerosis, 139, 205, 10.1016/S0021-9150(98)00107-5 Mourao, 1981, The binding of chondroitin 6-sulfate to plasma low density lipoprotein, Biochim Biophys Acta, 674, 178, 10.1016/0304-4165(81)90376-7 Bancells, 2009, High binding affinity of electronegative LDL to human aortic proteoglycans depends on its aggregation level, J Lipid Res, 50, 446, 10.1194/jlr.M800318-JLR200 Talusan, 2005, Analysis of intimal proteoglycans in atherosclerosis-prone and atherosclerosis-resistant human arteries by mass spectrometry, Mol Cell Proteomics, 4, 1350, 10.1074/mcp.M500088-MCP200 Stephens, 2010, Differential proteoglycan and hyaluronan distribution in calcified aortic valves, Cardiovasc Pathol, 20, 334, 10.1016/j.carpath.2010.10.002 Huang, 2008, Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development, J Lipid Res, 49, 521, 10.1194/jlr.M700329-JLR200 Kwon, 2008, Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points, Circulation, 117, 2919, 10.1161/CIRCULATIONAHA.107.754614 Neufeld, 2010, The renal artery ostium flow diverter: structure and potential role in atherosclerosis, Atherosclerosis, 211, 153, 10.1016/j.atherosclerosis.2010.01.024 Casscells, 1990, Immunohistochemical study of fibronectin in experimental myocardial infarction, Am J Pathol, 137, 801 Li, 2000, Basement membrane zone type XV collagen is a disulfide-bonded chondroitin sulfate proteoglycan in human tissues and cultured cells, J Biol Chem, 275, 22339, 10.1074/jbc.M000519200 Halfter, 1998, Collagen XVIII is a basement membrane heparan sulfate proteoglycan, J Biol Chem, 273, 25404, 10.1074/jbc.273.39.25404 Burg, 1996, Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules, J Biol Chem, 271, 26110, 10.1074/jbc.271.42.26110 Douglas, 2006, Fibrillogenesis of collagen types I, II, and III with small leucine-rich proteoglycans decorin and biglycan, Biomacromolecules, 7, 2388, 10.1021/bm0603746 Kadler, 2008, Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators, Curr Opin Cell Biol, 20, 495, 10.1016/j.ceb.2008.06.008 Lethias, 2006, A model of tenascin-X integration within the collagenous network, FEBS Lett, 580, 6281, 10.1016/j.febslet.2006.10.037 Barkalow, 1994, Interactions between fibronectin and chondroitin sulfate are modulated by molecular context, J Biol Chem, 269, 3957, 10.1016/S0021-9258(17)41727-3 Elefteriou, 2001, Binding of tenascin-X to decorin, FEBS Lett, 495, 44, 10.1016/S0014-5793(01)02361-4 Pentikainen, 1997, The proteoglycan decorin links low density lipoproteins with collagen type I, J Biol Chem, 272, 7633, 10.1074/jbc.272.12.7633 Camejo, 1988, Identification of Apo B-100 segments mediating the interaction of low density lipoproteins with arterial proteoglycans, Arteriosclerosis, 8, 368, 10.1161/01.ATV.8.4.368 Gordon, 2010, Collagens, Cell Tissue Res, 339, 247, 10.1007/s00441-009-0844-4 Wiberg, 2003, Complexes of matrilin-1 and biglycan or decorin connect collagen VI microfibrils to both collagen II and aggrecan, J Biol Chem, 278, 37698, 10.1074/jbc.M304638200 Brown, 1989, Characteristics of the in vitro interaction of a small proteoglycan (PG II) of bovine tendon with type I collagen, Matrix, 9, 468, 10.1016/S0934-8832(11)80016-8 Vogel, 1984, Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon, Biochem J, 223, 587, 10.1042/bj2230587 Nareyeck, 2004, Differential interactions of decorin and decorin mutants with type I and type VI collagens, Eur J Biochem, 271, 3389, 10.1111/j.1432-1033.2004.04273.x Moulton, 2004, Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis, Circulation, 110, 1330, 10.1161/01.CIR.0000140720.79015.3C Minomo, 2011, Biological characteristics of two lysines on human serum albumin in the high-affinity binding of 4Z,15Z-bilirubin-IXalpha revealed by phage display, FEBS J, 278, 4100, 10.1111/j.1742-4658.2011.08316.x Moosavi-Movahedi, 2007, A theoretical elucidation of bilirubin interaction with HSA's lysines: first electrostatic binding site in IIA subdomain, Biophys Chem, 125, 375, 10.1016/j.bpc.2006.09.013 Ghuman, 2005, Structural basis of the drug-binding specificity of human serum albumin, J Mol Biol, 353, 38, 10.1016/j.jmb.2005.07.075 Skalen, 2002, Subendothelial retention of atherogenic lipoproteins in early atherosclerosis, Nature, 417, 750, 10.1038/nature00804 Soto, 2012, Antiatherosclerotic effect of an antibody that binds to extracellular matrix glycosaminoglycans, Arterioscler Thromb Vasc Biol, 32, 595, 10.1161/ATVBAHA.111.238659